Nutex Health Inc. (NUTX)

NASDAQ: NUTX · USD

$213

+4.75 (+2.3%)· Recorded snapshot

Market cap	1.5B
Revenue (ttm)	846.7M
Net income (ttm)	179.9M
EPS (ttm)	$25.2
Shares out	6.8M
P/E (trailing)	8.4x
P/E (forward)	8.4x
Volume	104,852
Beta	2.00

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 846.7M
Net income (ttm): 179.9M
EPS (ttm): $25.2
P/E (trailing): 8.4x
P/E (forward): 8.4x
Market cap: 1.5B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Trzymaj

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E8.4

P25 n/aP50 n/aP75 n/a

Trailing P/E8.4

P25 n/aP50 n/aP75 n/a

ROE64.6

P25 n/aP50 n/aP75 n/a

ROIC61.9

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All NUTX indicators

Market & fundamental data

Available fields

245

Groups with data

Currency

USD

Showing 245 of 245 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001479681
Company name	Nutex Health Inc.
Country	United States
Country code	US
CUSIP number	67079U306
Earnings date	2026-11-05
Earnings time	amc
Employees	1,037
Employees change	191
Employees growth	22.58%
Enterprise value	$1.6B
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2011
In index	RUSSELL2000
Industry	Medical Care Facilities
Is primary listing	Yes
Is SPAC	No
ISIN number	US67079U3068
Last 10-K release date	2026-03-05
Last earnings date	2026-08-06
Last refreshed	2026-10-28
Last stock split date	2024-07-03
Last stock split type	Reverse
Market cap	$1.5B
Market cap category	Small-Cap
Next earnings date	2026-11-05
Options	No
Price	$213.00
Price currency	USD
Sector	Healthcare
SIC code	7389
Stock price date	2026-10-28
Symbol	NUTX
U.S. state	Texas
Website	https://www.nutexhealth.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	11.85%
EV/Earnings	8.93x
EV/EBIT	3.34x
EV/EBITDA	3.2x
EV/FCF	5.91x
EV/Sales	1.9x
FCF / EV yield	16.91%
FCF yield	18.55%
Forward EV/Sales	1.76x
Forward P/E	8.41x
Forward P/S	1.6x
Graham number	180.87061
Graham upside	-15.46%
Industry forward P/E	14.81x
Industry P/E	18.21x
Lynch fair value	$281.82
Lynch upside	31.72%
P/(FCF - SBC) ratio	5.59x
P/(OCF - SBC) ratio	5.43x
P/B ratio	3.61x
P/E ratio	8.44x
P/FCF ratio	5.39x
P/OCF ratio	5.24x
P/S ratio	1.73x
Price / tangible book value	4.07x
Price/EBITDA ratio	2.92x
Sector forward P/E	23.53x
Sector P/E	51.01x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	56.84%
EBITDA margin	59.32%
Effective tax rate	20.67%
FCF margin	32.11%
Gross margin	54.51%
Operating margin	56.84%
Pretax margin	40.57%
Profit margin	21.25%
Profit per employee	$173,499
Profitable quarters	4
Profitable years	2
Revenue per employee	$816,509
ROA	33.32%
ROA (5Y)	15.51%
ROCE	56.79%
ROE	64.56%
ROE (5Y)	-18.36%
ROIC	61.92%
ROIC (5Y)	27.6%
SBC / revenue	1.13%
Tax / revenue	8.38%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth	172.78%
EPS growth (QoQ)	43.87%
EPS growth 5Y	-1.21%
EPS growth quarters	2
EPS growth years	3
FCF growth	234.62%
FCF growth (Q)	29.16%
FCF growth (QoQ)	-57.4%
FCF growth 5Y	60.55%
Gross profit growth	6.59%
Gross profit growth (Q)	12.62%
Gross profit growth 3Y	422.91%
Gross profit growth 5Y	22.19%
Net income growth	219.32%
Net income growth (QoQ)	40.67%
Net income growth 5Y	11.17%
Net income growth quarters	2
Net income growth years	3
OCF growth	228.72%
OCF growth (Q)	25.47%
OCF growth (QoQ)	-54.71%
OCF growth 5Y	26.4%
Operating income growth	101.62%
Operating income growth (Q)	261.41%
Operating income growth 5Y	25.73%
Revenue growth	6.88%
Revenue growth (Q)	-13.62%
Revenue growth (QoQ)	-2.65%
Revenue growth 3Y	62.49%
Revenue growth 5Y	25.31%
Revenue growth years	3

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-7.8M
Depreciation and amortization	$21M
EBIT	$481.3M
EBITDA	$502.3M
EPS	$25.24
FCF per share	$39.70
Financing cash flow	$-160.4M
Free cash flow	$271.9M
Free cash flow minus SBC	$262.3M
Gross profit	$461.5M
Income taxes	$71M
Investing cash flow	$-9.1M
Net borrowing	$-22.6M
Net cash flow	$110.1M
Net income	$179.9M
Operating cash flow minus SBC	$270M
Operating income	$481.3M
Revenue	$846.7M
Stock-based compensation	$9.6M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	3.88
Book value per share	$57.62
Debt / EBITDA	0.69
Debt / equity	0.68
Debt / FCF	1.28
Goodwill	$13.9M
Interest coverage	24.33
Long-term assets	$379M
Long-term liabilities	$340.1M
Net cash (debt)	$-142.1M
Net cash / market cap	-9.7%
Net debt / EBITDA	0.28
Net debt / equity	0.28
Net debt / FCF	0.52
Piotroski F-Score	5
Property, plant and equipment	$340.9M
Shareholders' equity	$507.3M
Tangible book value	$359.8M
Tangible book value per share	$52.58
Total assets	$964.6M
Total cash	$205.2M
Total debt	$347.3M
Total liabilities	$457.3M
WACC	13.21%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.94
Current assets	$585.7M
Current liabilities	$117.2M
Current ratio	5
Inventory turnover	118.85
Net working capital	$281.3M
Quick ratio	4.79
Working capital	$468.4M
Working capital turnover	2.27

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-14.84%
Dividend yield	0%
Shareholder yield	-14.84%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$160.85
1D price change	2.28%
1M price change	-3.52%
1M total return	-3.52%
1W price change	6.72%
1W total return	6.72%
1Y price change	64.01%
1Y return CAGR	64.06%
1Y total return	64.01%
20-day SMA	$206.20
200-day SMA	$150.08
3M price change	42.81%
3M total return	42.81%
3Y price change	677.86%
3Y return CAGR	98.11%
3Y total return	677.86%
50-day SMA	$202.61
50-day SMA vs 200-day SMA	50over200
52-week high	$226.16
52-week high date	2026-10-06
52-week low	$83.99
52-week low date	2026-03-06
6M price change	91.67%
6M total return	91.67%
All-time high	$7,920.00
All-time high date	2022-04-04
All-time low	$4.16
All-time low date	2024-07-10
Average true range (ATR)	$10.78
Average volume	143.4K
Beta (1Y)	0.94
Beta (2Y)	2.13
Beta (5Y)	2
Change from 52-week high	-5.82%
Change from 52-week low	153.6%
Change from all-time high	-97.32%
Change from all-time low	5,004.69%
Change from open	1.87%
Day's gap	0.4%
Dollar volume	$22.3M
High price	$213.00
Low price	$209.09
Monthly RSI	54.45
Open price	$209.09
Position in 52-week range	100%
Previous close	$208.25
Price vs 150-day SMA	32.02%
Price vs 20-day SMA	2.98%
Price vs 200-day SMA	41.49%
Price vs 50-day SMA	4.81%
Relative volume	0.73
RSI	56.51
Sharpe ratio	0.95
Sharpe ratio (3Y)	1.11
Sortino ratio	1.55
Sortino ratio (3Y)	1.91
Volume	104.9K
Weekly RSI	62.6
YTD price change	29%
YTD total return	29%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	4.1M
Float percentage	60.53%
Shares change (QoQ)	-2.2%
Shares change (YoY)	14.84%
Shares held by insiders	32.87%
Shares held by institutions	36.15%
Shares outstanding	6.8M
Short % of float	29.85%
Short % of shares	18.07%
Short ratio	7.9 days

Deeper analysis on NUTX

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this NUTX report

Is a complete NUTX research report available?

No complete published report is available for Nutex Health Inc. (NUTX) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Nutex Health Inc. (NUTX)

Price

Financial snapshot

Fair-value bridge

Latest news · NUTX

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All NUTX indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on NUTX

Frequently asked questions